Keep your eyes on the skies: Annual Perseid meteor shower set to peak tonight
Stargazers are in for a shimmering show tonight as the annual Perseid meteor shower is set to reach its peak.
NASA says the fireball shower began last month and the celestial event is expected to peak tonight and tomorrow before ending on Aug. 23.
The space agency says the Perseids are best viewed in the Northern Hemisphere during the pre-dawn hours, but at times it's possible to view the streaks of colourful cosmic light as early as 10 p.m.
NASA says about 50 to 100 meteors are seen per hour during the shower, with meteors shooting across the sky at about 59 kilometres per second.
The U.S. space agency says every Perseid meteor is a tiny piece of the 26-kilometre-wide comet Swift-Tuttle, which swings near the sun every 133 years.
NASA says the meteor shower comes after earth passes through the debris of the comet, allowing the meteors to collide with our atmosphere and create the starry streaks.
This report by The Canadian Press was first published Aug. 12, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
8 minutes ago
- National Post
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
Article content Article content Q2 marked a critical inflection point in EB-003 development with mechanism confirmation, therapeutic opportunity expansion, IND-enabling progress, and continued strengthening of Enveric's differentiated neuroplastogen pipeline and IP platform. Q2 financial results were consistent with overall performance over the previous four quarters, and development costs were in line with budgeted IND-enabling activities. Article content Article content CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the second quarter ended June 30, 2025, and provided a comprehensive business update. Article content CEO Commentary Article content 'The second quarter of 2025 represented a period of focused execution across all key areas of our business, most notably with the advancement of EB-003, our lead drug candidate,' said Joseph Tucker, Ph.D., Director and CEO of Enveric. 'We disclosed important new data demonstrating that EB-003 engages both the 5-HT₂ A and 5-HT₁ B receptors through a dual mechanism of action. We believe this receptor pairing forms the foundation for a novel pharmacological class. With this discovery, we believe EB-003 has emerged as a first-in-class therapeutic candidate with a dual mechanism that represents a unique therapeutic target with real-world clinical utility.' Article content 'This new pharmacological class is defined by agonism at the 5-HT₁ B receptor, which modulates affective tone, impulsivity, and reward pathways, as well as concurrent partial agonism at the 5-HT₂ A receptor, which supports cortical neuroplasticity. We believe this novel and unique profile has the potential to promote adaptive rewiring of brain circuits (i.e. neuroplasticity) while stabilizing emotional reactivity, motivational control, and behavioral regulation (i.e., generally psychological stability). It is expected to unlock the therapeutic benefits of serotonin mediated plasticity and guide those effects toward outcomes that are durable, broadly accessible, and clinically relevant for real-world patient populations.' Article content 'By targeting this specific set of neural receptors, the intent is for EB-003 to recalibrate emotional reactivity, facilitate extinction of maladaptive fear responses, and restore motivational tone. These are mechanisms believed to support lasting recovery in conditions such as post-traumatic stress disorder (PTSD), treatment resistant depression, and generalized anxiety. The addition of 5-HT₁ B agonism is intended to guide plasticity into emotionally grounded outcomes; thus, the designation of EB-003 as a first-in-class drug candidate.' Article content 'With these advances, EB-003 continues to differentiate itself in a competitive neuropsychiatric drug development landscape, with pre-IND test data for EB-003 pointing to a fast acting, durable, and non-hallucinogenic treatment for serious mental health conditions where currently available therapies are either too slow, poorly tolerated, or not very effective.' 'Beyond EB-003, we made meaningful progress in expanding our intellectual property portfolio, which remains a foundational pillar of our strategy. During the second quarter, we secured an additional patent grant in our EVM-301 portfolio and patent allowances across multiple distinct chemical classes in our EVM-301 and EVM-401 portfolios, further reinforcing Enveric's leadership in the discovery of rationally designed neuroplastogens. With a growing portfolio of issued patents and new filings underway, we are seeking to build a durable, competitive moat around our lead assets and future pipeline candidates.' Article content 'Looking ahead to the remainder of 2025 and into 2026, we remain sharply focused on filing an Investigational New Drug (IND) application for EB-003 and preparing for its first-in-human study. We also continue to benefit from ongoing dialogue and growing interest from established pharmaceutical companies with a strategic focus in neuropsychiatry, which underscores the increasing relevance of our platform in a field that has lacked innovation for far too long.' Article content Second Quarter and Recent Corporate Highlights Article content Revealed EB-003's Dual Mechanism of Action: Enveric confirmed that EB-003, its lead compound, engages both 5-HT₂ A (partial agonist) and 5-HT₁ B (agonist) receptors, a dual mechanism not previously reported in clinical-stage neuropsychiatric drug candidates. This unique pharmacology forms the basis of a new pharmacological class designed to promote therapeutic neuroplasticity, emotional recalibration, and enhanced control over affective and behavioral responses without the need for hallucinogenic intervention. Progressed Toward IND Submission: IND-enabling studies for EB-003 remain on track, with submission to the U.S. FDA anticipated in early 2026. Enveric continues to generate data supporting EB-003's safety, tolerability, and pharmacokinetic profile, including results supporting extended, repeat-dose oral use. Expanded Therapeutic Opportunity: PTSD: In a validated preclinical model, EB-003 produced rapid extinction of contextual fear responses following a single administration. Chronic Depression: Mice treated with EB-003 exhibited a statistically significant reduction in behavioral despair (p < 0.01) in the forced swim test, a standard model of antidepressant efficacy. Dosing Profile: Supporting data indicate EB-003 is well tolerated with daily oral administration, distinguishing it from hallucinogenic agents that require intensive supervision and infrequent dosing. Article content Intellectual Property Expansion Article content Broadened Patent Portfolio Across Two Molecular Classes: Filed a new patent application covering a novel chemical structure with potential relevance in neurodegenerative and cognitive indications. Received a Notice of Allowance from the U.S. Patent and Trademark Office for a second mescaline-derivative analogs patent, reinforcing Enveric's leadership in modifying classical psychedelic frameworks into non-hallucinogenic, drug-like structures. Secured a composition of matter patent on N-Substituted Tryptamine Derivatives, extending the Company's IP coverage of EVM-301 molecules into this new class of drugs and the serotonergic field. Article content Second Quarter 2025 Financial Results Article content Net loss attributable to common stockholders was $2.5 million for the quarter ending June 30, 2025, or $0.97 per share, compared to a net loss of $1.9 million, or $3.72 per share, for the same period in 2024. The net loss for the quarter included approximately $0.2 million in non-cash expenses related to stock-based compensation and other non-cash charges. As of June 30, 2025, Enveric had cash and cash equivalents of $2.8 million. The Company continues to fund its operations through the use of various financing tools. The Company has raised net proceeds of $4.9M for the six months ended June 30, 2025. Article content About Enveric Biosciences Article content Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric's lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂ A and 5-HT₁ B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience. For more information, please visit Article content Forward-Looking Statements Article content This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. Article content A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Article content Article content Article content Article content Contacts Article content Investor Relations Tiberend Strategic Advisors, Inc. David Irish (231) 632-0002 dirish@ Media Relations Tiberend Strategic Advisors, Inc. Casey McDonald (646) 577-8520 cmcdonald@ Article content
National Observer
3 hours ago
- National Observer
Trump's latest attack on carbon research will hamper Canadian scientists
In early August, Debra Wunch, an atmospheric physicist at the University of Toronto, got wind that the Trump administration might destroy the NASA satellite that underpins her career. "It's devastating," said Wunch, who studies how many greenhouse gases Toronto emits and the impact of boreal forests on the carbon cycle. "These satellites have been a fundamental part of my career since 2007 — I've been working with these data for a very long time." The satellite, OCO-2, is part of NASA's Orbiting Carbon Observatory (OCO) project and measures where on the Earth's surface carbon dioxide is being emitted or absorbed. The data are detailed enough that researchers can pinpoint carbon dioxide emissions from a specific source, such as a power plant or wildfire, and track changes in the growing season. The data are widely used by scientists, farmers and the fossil fuel industry. Last week, NPR reported that the Trump administration asked employees at NASA to create plans to end at least two satellite missions, including the OCO project, as part of Trump's proposed budget cuts. If those plans go through — Trump's budget needs to be approved by Congress, which isn't guaranteed — the OCO-2 satellite will be destroyed when it burns up re-entering the atmosphere after being abandoned. Although budget cuts are being used to justify the move, the Trump administration has made similar efforts to dismantle other programs dedicated to monitoring climate change. Soon after taking office, he forced US government researchers at the National Oceanic and Atmospheric Administration (NOAA) to stop all collaboration with "foreign nationals" — a move critics decried as a "body blow to climate research." The administration has also stopped tracking the cost of climate-related disasters, and is pushing the country's Environmental Protection Agency to eliminate the legal basis for some of the US's key climate rules — with "indispensible" help from climate denying Canadian economist Ross McKitrick — among dozens of other moves to roll back climate efforts. Russ Vought, the director of the Trump White House Office of Management and Budget — the office responsible for drafting the White House's budget proposal — was a co-author of the Heritage Foundation's Project 2025. In that document, he wrote that"the Biden Administration's climate fanaticism will need a whole-of-government unwinding." The Trump administration wants to eliminate a NASA satellite mission that pinpoints carbon dioxide emissions from a specific source, such as a power plant or wildfire, and track changes in the growing season. The OCO project also operates a second device on the International Space Station, OCO-3. Last month, NASA announced it is accepting proposals from companies and universities that want to cover the machine's operating costs. The devices are still functional, and an official review by NASA in 2023 recommended continuing the mission for at least three more years. It concluded the satellite is of "high utility" because it helps agencies track industrial emissions, the planet's carbon cycle and to monitor compliance with international climate commitments. Operating both devices costs about $15 million a year — roughly two per cent of the $750 million it cost NASA to build them, David Crisp, the NASA scientist who designed the instruments and managed the missions until 2022, told NPR. Wunch is one of thousands of researchers, including several Canadians, who have worked on the OCO or rely on data collected by the devices to better understand the climate crisis and whether our efforts to fight it are working. OCO-2 was the first satellite dedicated to making CO2 measurements with enough accuracy and precision to answer scientific questions about the carbon cycle, said Ray Nassar, a scientist with Environment and Climate Change Canada who was the first person to use OCO-2 data to calculate emissions specific to coal-fired power plants in 2017. "OCO-2 was extremely important in giving us the first observations of that kind that could do that," he said. "They're the leading satellites making this type of measurement, and there's already been a significant investment to get them up in space. To just turn them off at this point, we would lose a valuable source of data" The satellite circles the Earth from south to north, monitoring CO2 in the atmosphere in narrow bands roughly one kilometer wide. This gives researchers enough precision to identify where the gas is being emitted or absorbed, a level of detail unmatched by any other satellites currently in orbit. "Because it's measuring carbon dioxide all around the world, we're able to get more of an idea of regionally, where carbon is being absorbed and where it's being emitted," said Brendan Bryne, a Canadian researcher who worked on the OCO project at NASA's Jet Propulsion Lab between 2018 and 2024. Japan has three CO2-measuring satellites in orbit, but they scan a bigger area than the OCO ones. The European Space Agency is planning to send three satellites that can collect similar data on CO2 emissions into space late next year. OCO-2 and OCO-3 can also measure a specific type of photon that plants release during photosynthesis, which researchers can use to track changes in the growing season, as well as when boreal forests start re-absorbing carbon after a wildfire. Losing the satellites will prevent her and other researchers from conducting most of this type of research, said Wunch. "Without commenting on a specific policy decision by any country, turning off satellites that are delivering valuable data is generally a bad thing to do," said Nassar. Simon Donner, a climate scientist at the University of British Columbia, wrote in an email that Trump's proposal is "a foolish decision for financial reasons alone. The vast majority of the cost of satellites is in their construction and launch. Once they are in space, it is relatively cheap to keep them operating, and you get downstream economic benefits from the use of the data." Canada's National Observer reached out to NASA asking about the proposed cuts, but didn't receive a response. Environment and Climate Change Canada couldn't provide a response by deadline to a question about whether Canada could take over the project's operational costs, if the US were willing to transfer the mission. Wunch was clear about the toll that could come if NASA is forced to abandon the OCO mission: "I'm just very sad," she said.
Globe and Mail
7 hours ago
- Globe and Mail
US Firm Achieves Second Thorium Breakthrough at Idaho National Lab's Reactor
The glowing blue core of the Advanced Test Reactor at Idaho National Laboratory. CHICAGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Clean Core Thorium Energy (CCTE) announces the second major milestone for its patented Advanced Nuclear Energy for Enriched Life (ANEEL™) fuel, which has now reached a burnup level of over 45 gigawatt-days per metric ton (GWd/MTU) in the Advanced Test Reactor (ATR) at the U.S. Department of Energy's Idaho National Laboratory (INL). This achievement outpaces the capabilities of conventional nuclear fuels used in Pressurized Heavy Water Reactors (PHWRs) and CANDU reactors. In May 2024, twelve ANEEL™ fuel rodlets were loaded into the ATR for irradiation to achieve three burnup level targets. The first successful irradiation of four rodlets surpassed 20 GWd/MTU last year. CCTE is excited to report that the second set of four rodlets have exceeded 45 GWd/MTU—six to seven times the average discharge burnup for PHWR/CANDU reactors that are designed to use natural uranium fuel. The newly irradiated rodlets are currently cooling in the ATR water pool and will soon be transferred to INL's Materials and Fuels Complex (MFC) for detailed post-irradiation examination. The final four rodlets will remain in the ATR for continued irradiation, with expected burnup levels exceeding 60 GWd/MTU. These results underscore ANEEL™ fuel's potential to redefine performance and sustainability standards in the nuclear industry. Developed by CCTE, the fuel uniquely combines thorium with High-Assay Low-Enriched Uranium (HALEU) to offer a safer, more efficient, and proliferation-resistant alternative for existing and future PHWR and other CANDU reactor fleets worldwide. Mehul Shah, Founder and CEO of CCTE Thorium Energy, said: 'This second burnup milestone is a transformative moment for CCTE and for the future of nuclear energy. ANEEL™ fuel is not just demonstrating superior technical performance—it's proving that thorium-based solutions can meaningfully address global challenges of energy security, nuclear waste, and proliferation. Our successful partnership with INL is helping unlock a new era for advanced nuclear fuels.' Dr. Koroush Shirvan, Head of Fuel Design at CCTE and Professor at MIT, added: 'The collection of this data positions ANEEL™ fuel as a prime candidate for near-term deployment in PHWRs' Dr. Michael Worrall, Technical Lead for the CCTE ATR Irradiation at INL, noted: 'ANEEL's performance in the ATR is a strong indicator of the promise thorium-based fuels hold in supporting future energy goals and diversifying the nuclear fuel landscape.' Dr. Daniel Wachs, National Technical Director for the DOE Advanced Fuels Campaign (AFC) and Nuclear Fuels and Materials Directorate Fellow at INL, said: 'The partnership between INL and CCTE is a great example of how the INL and private sector innovators can collaborate to rapidly develop advanced nuclear technologies with the potential to impact the marketplace worldwide.' Gamma scanning of ANEEL irradiated capsules at the INL's hot cell facility. About Clean Core Thorium Energy Clean Core Thorium Energy is a U.S.-based nuclear innovation company developing advanced nuclear fuel solutions using thorium and HALEU. Its patented ANEEL™ fuel is designed to enhance the safety, economics, and nonproliferation profile of PHWRs and CANDU reactors while drastically reducing nuclear waste. Learn more at Follow us on LinkedIn and X. About Idaho National Laboratory Managed by Battelle Energy Alliance for the U.S. Department of Energy's Office of Nuclear Energy, INL is the nation's leading center for nuclear energy research and development. INL is celebrating 75 years of scientific leadership in energy, security, and environmental innovation. Learn more at Follow INL on Facebook, Instagram, LinkedIn, and X. Media Contact: Milan Shah Email: info@
